China's Infant Formula Sales Likely Continue to Decline in 2024 -- Market Talk

Dow Jones01-18

0426 GMT - China's infant formula market sales will likely keep falling this year due to the shrinking infant population, but at a slower pace than in 2023, Citi analysts say in a research note. China's infant population could decline 5% in 2024, compared with 9% in 2023, the analysts say. Citi expects intensified market competition and consolidation in 2024. China Feihe will likely keep facing topline pressure, gross profit margin contraction, and declining earnings in 2024. Health & Happiness (H&H) International Holdings' early move to a health supplement business will bear fruit and continue to drive growth in 2024, the analysts say. A2 Milk's 1H result might be better than expected as the company recently reiterated its 2024 earnings guidance, they add. (sherry.qin@wsj.com)

 

(END) Dow Jones Newswires

January 17, 2024 23:26 ET (04:26 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment